BEDFORD, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvin therapeutics for the treatment of eye disease. The newly-reported results demonstrate the efficacy of resolvins in multiple animal models of ocular disease, including age-related macular degeneration (AMD) and dry eye. In addition, the data demonstrate that, upon topical dosing, resolvin compounds achieve therapeutic concentrations at the level of the retina, offering the potential for a topical drug, administered as eye drops, to treat retinal disease. Data on the company’s resolvin drug candidates, including the lead development candidate for eye disease, RX-10008, were presented in eight oral and poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held April 27 to May 1, 2008.
